Pacific Biosciences Of California, Inc. income statement

In fiscal 2025, Pacific Biosciences Of California, Inc. reported revenue of $160m, up 3.9% on the year before, operating income of −$554m (a -346.2% margin) and net income of −$546m, or −$1.82 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pacific Biosciences Of California, Inc.: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	2	34	26	28	61	93	91	93	79	91	79	131	128	201	154	160	159
Cost of revenue	—	—	21	25	22	37	39	47	59	54	56	46	72	79	148	117	114	101
Gross profit	0	2	13	1	6	23	53	44	35	25	35	33	59	49	53	37	46	58
Research and development	76	112	76	48	45	48	60	68	65	63	60	64	113	193	187	135	97	88
Selling, general and administrative	12	30	47	48	39	38	45	48	59	63	75	73	124	161	170	175	141	130
Operating income	—	—	−110	−94	−78	−63	−29	−71	−90	−101	−101	−104	−210	−307	−334	−474	−554	−133
Interest expense	—	—	0	0	2	3	3	3	3	2	3	0	13	15	14	13	7	7
Income before tax	—	—	—	—	—	—	—	—	—	—	−84	29	−275	−314	−318	−310	−546	−131
Income tax	—	—	—	—	—	—	—	—	—	—	—	—	−94	0	−11	0	0	1
Net income	−88	−140	−109	−94	−79	−66	−32	−74	−92	−103	−84	29	−181	−314	−307	−310	−546	−131
Diluted EPS	−$173.03	−$14.10	−$2.03	−$1.69	−$1.26	−$0.94	−$0.42	−$0.83	−$0.87	−$0.76	−$0.55	$0.17	−$0.89	−$1.40	−$1.21	−$1.59	−$1.82	−$0.43
Diluted shares (average)	—	—	54m	56m	63m	70m	76m	89m	106m	135m	153m	175m	204m	225m	254m	288m	300m	305m
EBITDA	—	—	−104	−88	−72	−59	−25	−67	−81	−94	−93	−98	−203	−298	−323	−461	−541	−123

US$ millions unless shown otherwise. Fiscal quarters.

Pacific Biosciences Of California, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	40	39	37	40	38	45	37	39
Cost of revenue	30	29	39	25	23	28	24	26
Gross profit	10	10	−1	15	16	17	13	13
Research and development	26	27	29	23	23	23	20	23
Selling, general and administrative	44	42	40	36	31	34	31	33
Operating income	−64	−153	−429	−45	−39	−41	−8	−45
Interest expense	4	3	2	2	2	2	2	2
Income before tax	−61	3	−426	−42	−38	−40	−8	−45
Income tax	0	0	−0	0	0	0	0	0
Net income	−61	2	−426	−42	−38	−40	−8	−45
Diluted EPS	−$0.22	−$0.44	−$1.44	−$0.14	−$0.13	−$0.13	−$0.03	−$0.14
EBITDA	−60	−150	−424	−42	−36	−38	−6	−42

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GRAL vs PACB PACB vs QTRX CYRX vs PACB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Pacific Biosciences Of California, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pacific Biosciences Of California, Inc.